Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features

The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as “amplified,” inclusive of cases with a HER2 copy number less than 4. The 2018 A...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Human pathology Ročník 83; s. 7 - 13
Hlavní autori:	Zare, Somaye Y., Lin, Leo, Alghamdi, Abrar G., Daehne, Svenja, Roma, Andres A., Hasteh, Farnaz, Dell'Aquila, Marie, Fadare, Oluwole
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.01.2019 Elsevier Limited
Predmet:	Adult Aged Aged, 80 and over Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - classification Breast Neoplasms - genetics Breast Neoplasms - pathology Centromere enumeration probe for chromosome 17 Chromosome 17 monosomy Chromosomes Chromosomes, Human, Pair 17 - genetics Female Fluorescence in situ hybridization Gene Dosage Gene Expression Profiling - methods Genes, erbB-2 Human epidermal growth factor receptor 2 Humans Hybridization Immunohistochemistry Lymphatic system Middle Aged Receptor, ErbB-2 - analysis Receptor, ErbB-2 - genetics Tumors Young Adult Chromosome 17 monosomy Breast cancer Human epidermal growth factor receptor 2 Centromere enumeration probe for chromosome 17 Fluorescence in situ hybridization
ISSN:	0046-8177, 1532-8392, 1532-8392
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!